EP Vantage Releases New Half Year Reviews for the Pharma and Medtech Industries
London, Boston, Tokyo - 20 August 2015 - The first half of 2015 has continued to confound the naysayers of the pharma industry, with deal making, venture funding and share price indices all going strong. Meanwhile, the medtech sector is much changed from a year or even six months ago, with some of the biggest names shifting to take a larger share of the market and others moving out of it altogether.
Pharma & Biotech Half-Year Review 2015 Highlights
“The big question as ever with the industry is how much is too much but so far, it looks as if 2015 will not be the year when the bottom falls out of the market,” said Lisa Urquhart, EP Vantage editor and co-author of the report. “It looks for now like the sector is heading for what will hopefully be a gentle slowdown rather than a full-blown crash.”
The full version of the Pharma & Biotech Half-Year Review 2015 can be at downloaded for free at www.evaluategroup.com/PharmaBiotechHalfYear2015
Medtech 2015 Half-Year Review Highlights
“With the huge and exciting changes that have gripped the industry over the past year having for the most part been brought to their respective conclusions, the sector seems to have attained a level of stability,” said Elizabeth Cairns, EP Vantage medtech reporter and co-author of the report. “But start-ups are facing a worsening funding gap, and it will be crucial that this eases if a steady flow of safe and effective medical technologies is to be maintained.”
The full version of the Medtech 2015 Half-Year Review report can be downloaded for free at www.evaluategroup.com/MedtechHalfYear2015
About Evaluate Ltd
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluate.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP @epclinicaltrial, @epvantage.
Issued for and on behalf of Evaluate by Instinctif Partners.
For more information please contact: email@example.com
Melanie Toyne-SewellManaging Partner